KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals has reported Other Non-Current Liabilities over the past 9 years, most recently at $19.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, changed N/A, while the annual FY2025 figure was $19.1 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $19.1 million at Amneal Pharmaceuticals, down from $32.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $79.2 million in Q2 2022 and troughed at $433000.0 in Q2 2024.
  • A 5-year average of $31.6 million and a median of $26.2 million in 2024 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 99.05% in 2023 and later surged 1792.61% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $38.9 million in 2021, then plummeted by 75.2% to $9.6 million in 2022, then grew by 22.04% to $11.8 million in 2023, then surged by 122.37% to $26.2 million in 2024, then decreased by 26.94% to $19.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AMRX at $19.1 million in Q4 2025, $32.6 million in Q3 2025, and $8.2 million in Q2 2025.